ABSTRACT
Our interest in lymphatic mapping was raised when one of us witnessed the first sentinel lymph-node (SLN) biopsy outside the John Wayne Cancer Institute performed by Merrick I Ross at the MD Anderson Cancer Center in 1991. With interest and, admittedly, a fair dose of skepticism, the novel approach was introduced in Europe in 1993. At The Netherlands Cancer Institute, we believed that nuclear medicine had an important role in lymphatic mapping. The cooperation of the nuclear medicine physicians was solicited from the outset, and the gamma probe, then gathering dust, was given new purpose.
